Literature DB >> 198725

Observations on the algogenic actions of adenosine compounds on the human blister base preparation.

Tirza Bleehen1, C A Keele.   

Abstract

The action of the adenyl compounds adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and adenosine was studied on the human blister base preparation. All 4 adenyl compounds produced pain which was slow in onset and not maintained. The threshold concentration for pain was of the order of 1-3 micron. The slopes of log concentration:pain intensity plots were relatively shallow and for moderate to severe pain a 100-fold increase of the threshold concentration was required. The adenyl compounds resembled 5-hydroxytryptamine and bradykinin with respect to onset and duration of action but were less potent. On the other hand, for threshold effects they were more potent than acetylcholine or potassium. Evidence was found for an interaction of adenyl compounds with 5-hydroxytryptamine but not with potassium, acetylcholine or bradykinin. Cyclic adenosine 3',5'-monophosphate or the chelation of extracellular calcium or magnesium were shown not to be involved in the algogenic action of adenyl compounds and the action of adenyl compounds on the rabbit isolated jejunum too was found to be unrelated to their algogenic action on the human blister base preparation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 198725     DOI: 10.1016/0304-3959(77)90066-5

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  74 in total

1.  Excitatory effect of P2X receptor activation on mesenteric afferent nerves in the anaesthetised rat.

Authors:  A J Kirkup; C E Booth; I P Chessell; P P Humphrey; D Grundy
Journal:  J Physiol       Date:  1999-10-15       Impact factor: 5.182

2.  In vivo pathway of thermal hyperalgesia by intrathecal administration of alpha,beta-methylene ATP in mouse spinal cord: involvement of the glutamate-NMDA receptor system.

Authors:  M Tsuda; S Ueno; K Inoue
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 3.  Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction.

Authors:  G Burnstock
Journal:  J Anat       Date:  1999-04       Impact factor: 2.610

4.  Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X(3) allosteric modulator, cibacron blue.

Authors:  M F Jarvis; C T Wismer; E Schweitzer; H Yu; K J Lynch; E C Burgard; E A Kowaluk
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  The Meissner corpuscle revised: a multiafferented mechanoreceptor with nociceptor immunochemical properties.

Authors:  M Paré; R Elde; J E Mazurkiewicz; A M Smith; F L Rice
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

6.  Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia.

Authors:  M Tominaga; M Wada; M Masu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

7.  Expression of ecto-ATPase NTPDase2 in human dental pulp.

Authors:  X Liu; L Yu; Q Wang; J Pelletier; M Fausther; J Sévigny; H S Malmström; R T Dirksen; Y F Ren
Journal:  J Dent Res       Date:  2011-12-14       Impact factor: 6.116

8.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

Review 9.  Nucleotide signaling and cutaneous mechanisms of pain transduction.

Authors:  G Dussor; H R Koerber; A L Oaklander; F L Rice; D C Molliver
Journal:  Brain Res Rev       Date:  2008-12-31

Review 10.  Crossing the pain barrier: P2 receptors as targets for novel analgesics.

Authors:  C Kennedy; T S Assis; A J Currie; E G Rowan
Journal:  J Physiol       Date:  2003-09-26       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.